| Stability of curcumin in buffer solutions and characterization of its degradation products | Journal of Pharmaceutical and Biomedical Analysis | 1997 | 1.2K |
| Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update | Hepatology International | 2017 | 955 |
| Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma | Hepatology International | 2010 | 825 |
| Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis | Journal of Thoracic Oncology | 2017 | 432 |
| Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 | Proceedings of the National Academy of Sciences of the United States of America | 2012 | 366 |
| Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial | Lancet Oncology, The | 2012 | 331 |
| Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis | JAMA Oncology | 2018 | 277 |
| Aptamer-based tumor-targeted drug delivery for photodynamic therapy | ACS Nano | 2010 | 258 |
| Folic acid-conjugated chitosan nanoparticles enhanced protoporphyrin IX accumulation in colorectal cancer cells | Bioconjugate Chemistry | 2010 | 216 |
| Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB | Molecular Cell | 2007 | 203 |
| The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients | Oncotarget | 2016 | 165 |
| Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease | International Journal of Radiation Oncology Biology Physics | 2004 | 139 |
| Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma | British Journal of Cancer | 2013 | 137 |
| Autophagy promotes resistance to photodynamic therapy-induced apoptosis selectively in colorectal cancer stem-like cells | Autophagy | 2014 | 129 |
| Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor | American Journal of Respiratory and Critical Care Medicine | 2011 | 129 |
| BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells | Biochemical Pharmacology | 2000 | 109 |
| Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-κB DNA-binding activity | Journal of Pineal Research | 2016 | 107 |
| Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis | Journal of Hepatology | 2019 | 106 |
| ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors | Cancer Letters | 2013 | 106 |
| The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution | Blood | 2012 | 103 |
| Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells | British Journal of Cancer | 1999 | 103 |
| Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer | Current Opinion in Oncology | 2015 | 102 |
| Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil | Journal of Hepatology | 2011 | 102 |
| Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways | Biochemical Journal | 2012 | 99 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis | Journal of Thoracic Oncology | 2015 | 96 |
